ZA202407659B - Compositions having improved bioavailability of therapeutics and uses thereof - Google Patents

Compositions having improved bioavailability of therapeutics and uses thereof

Info

Publication number
ZA202407659B
ZA202407659B ZA2024/07659A ZA202407659A ZA202407659B ZA 202407659 B ZA202407659 B ZA 202407659B ZA 2024/07659 A ZA2024/07659 A ZA 2024/07659A ZA 202407659 A ZA202407659 A ZA 202407659A ZA 202407659 B ZA202407659 B ZA 202407659B
Authority
ZA
South Africa
Prior art keywords
disclosed
present specification
compositions
therapeutics
fibrates
Prior art date
Application number
ZA2024/07659A
Other languages
English (en)
Inventor
Daniel Gooding
John Brew
Robin M Bannister
Original Assignee
Trx Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/058180 external-priority patent/WO2022207580A2/en
Application filed by Trx Biosciences Ltd filed Critical Trx Biosciences Ltd
Publication of ZA202407659B publication Critical patent/ZA202407659B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2024/07659A 2022-03-14 2024-10-09 Compositions having improved bioavailability of therapeutics and uses thereof ZA202407659B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263269330P 2022-03-14 2022-03-14
PCT/EP2022/058180 WO2022207580A2 (en) 2021-03-27 2022-03-28 Compositions having improved bioavailability of therapeutics
PCT/EP2023/056506 WO2023174948A2 (en) 2022-03-14 2023-03-14 Compositions having improved bioavailability of therapeutics and uses thereof

Publications (1)

Publication Number Publication Date
ZA202407659B true ZA202407659B (en) 2026-01-28

Family

ID=85571360

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/07659A ZA202407659B (en) 2022-03-14 2024-10-09 Compositions having improved bioavailability of therapeutics and uses thereof

Country Status (7)

Country Link
EP (1) EP4493151A2 (cg-RX-API-DMAC10.html)
JP (1) JP2025509680A (cg-RX-API-DMAC10.html)
AU (1) AU2023233811A1 (cg-RX-API-DMAC10.html)
CA (1) CA3245873A1 (cg-RX-API-DMAC10.html)
IL (1) IL315617A (cg-RX-API-DMAC10.html)
WO (1) WO2023174948A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA202407659B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4784247A1 (en) * 2023-09-28 2026-08-05 The Regents Of The University Of California Methods and compositions of treating age-related conditions
WO2025093572A1 (en) * 2023-10-29 2025-05-08 TRx Biosciences Limited Solid dispersion compositions and uses thereof
WO2026053168A1 (en) * 2024-09-06 2026-03-12 Graviton Bioscience Bv Amorphous forms of a rock2 inhibitor and formulations thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US20020028813A1 (en) * 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
JP5758630B2 (ja) * 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Parp阻害剤としてのピリダジノン誘導体
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
CN102307576A (zh) * 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
CN101507707B (zh) * 2009-04-08 2011-01-19 邓菊娟 一种盐酸法舒地尔脂微球制剂及其制备方法
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
CN102813639B (zh) * 2011-06-08 2014-04-30 中国疾病预防控制中心寄生虫病预防控制所 甲苯达唑软胶囊剂
US9073944B2 (en) * 2012-02-21 2015-07-07 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
AU2014360537B2 (en) * 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
ES2975417T3 (es) * 2017-03-03 2024-07-05 Inspirna Inc Formulaciones con estabilidad mejorada
WO2020079706A1 (en) * 2018-10-15 2020-04-23 Cipla Limited Pharmaceutical formulation
WO2020217235A1 (en) * 2019-04-24 2020-10-29 Aizant Drug Research Solutions Private Limited Solid dosage form of dasatinib
CN113546045B (zh) * 2021-08-18 2022-11-11 浙江大学 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用

Also Published As

Publication number Publication date
IL315617A (en) 2024-11-01
CA3245873A1 (en) 2023-09-21
EP4493151A2 (en) 2025-01-22
WO2023174948A2 (en) 2023-09-21
AU2023233811A1 (en) 2024-09-19
WO2023174948A3 (en) 2023-10-26
JP2025509680A (ja) 2025-04-11

Similar Documents

Publication Publication Date Title
WO2022207580A3 (en) Compositions having improved bioavailability of therapeutics
WO2023174948A3 (en) Compositions having improved bioavailability of therapeutics and uses thereof
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
EA201290108A1 (ru) Составы в виде везикул
MX2013006598A (es) Inhibidores de la amida hidrolasa de acidos grasos (faah).
UA102478C2 (en) Capsule composition
GB2459809A (en) Fatty acid formulations and methods of use thereof
PH12012501054A1 (en) Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
IN2014DN08449A (cg-RX-API-DMAC10.html)
BR112013020167A2 (pt) melhoradores de permeação para formulações tópicas
CN104039303A (zh) 含有高浓度的咖啡因和烟酰胺的化妆品组合物
ATE413865T1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
MX2009009838A (es) Esteres de acidos grasos de glucocorticoides como agentes antiinflamatorios y anti-cancer.
EA201590591A1 (ru) Способ приготовления геля на основе полифенолов гранатовой кожуры для лечения воспалительных заболеваний в гинекологии
JO2324B1 (en) Pharmaceutical compounds for topical oral use
EP4470621A3 (en) Use of sodium alkyl sulfate
CA2910103C (en) Topical composition for enhancing skin sensitivity and use thereof
PH12021550391A1 (en) Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient
MX351222B (es) Composición transparente o translúcida.
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
CN102271652B (zh) 含有共轭亚油酸的纳米水乳液组合物
CR20230257A (es) Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d
CA2865557C (fr) Formulation gelifiante a base de gluconate de calcium
BR112022017963A2 (pt) Composição farmacêutica para prevenção ou tratamento de esteato-hepatite não alcoólica